John D. Sheppard

5.0k total citations · 2 hit papers
144 papers, 3.6k citations indexed

About

John D. Sheppard is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, John D. Sheppard has authored 144 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Ophthalmology, 54 papers in Public Health, Environmental and Occupational Health and 24 papers in Molecular Biology. Recurrent topics in John D. Sheppard's work include Ocular Surface and Contact Lens (54 papers), Glaucoma and retinal disorders (29 papers) and Allergic Rhinitis and Sensitization (21 papers). John D. Sheppard is often cited by papers focused on Ocular Surface and Contact Lens (54 papers), Glaucoma and retinal disorders (29 papers) and Allergic Rhinitis and Sensitization (21 papers). John D. Sheppard collaborates with scholars based in United States, Canada and United Kingdom. John D. Sheppard's co-authors include David G. Cooper, Patricia B. Williams, S. S. Samudre, Timothy L. Comstock, Darwin Lyew, Chandler R. Dawson, Paul Courtright, J Schachter, Raynald Laprade and Catherine Jumarie and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Environmental Science & Technology.

In The Last Decade

John D. Sheppard

141 papers receiving 3.4k citations

Hit Papers

Adalimumab for prevention of uveitic flare in patients wi... 2016 2026 2019 2022 2016 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
    2016 331 citations Quan Dong Nguyen, Pauline T. Merrill et al. The Lancet profile →
  2. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape
    2023 66 citations John D. Sheppard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John D. Sheppard United States 33 1.4k 1.3k 544 539 398 144 3.6k
Judith Flanagan Australia 23 323 0.2× 521 0.4× 326 0.6× 807 1.5× 52 0.1× 44 2.2k
Makoto Itoh Japan 44 57 0.0× 368 0.3× 295 0.5× 1.6k 3.0× 210 0.5× 349 7.3k
Liqiang Wang China 27 271 0.2× 341 0.3× 515 0.9× 956 1.8× 13 0.0× 176 3.3k
Gert Doekes Netherlands 45 93 0.1× 1.7k 1.3× 78 0.1× 334 0.6× 1.2k 3.1× 144 5.7k
Naoki Inoue Japan 40 105 0.1× 213 0.2× 55 0.1× 1.2k 2.3× 32 0.1× 206 5.0k
Els Adriaens Belgium 25 61 0.0× 173 0.1× 59 0.1× 177 0.3× 56 0.1× 83 1.9k
Jingjing Wang China 29 292 0.2× 110 0.1× 467 0.9× 879 1.6× 14 0.0× 173 3.2k
Dongmei Deng Netherlands 33 90 0.1× 241 0.2× 86 0.2× 898 1.7× 15 0.0× 132 4.2k
Viswanath P. Kurup United States 47 21 0.0× 816 0.6× 259 0.5× 792 1.5× 2.1k 5.3× 222 7.8k
Yoshimi Niwano Japan 33 90 0.1× 138 0.1× 205 0.4× 663 1.2× 16 0.0× 150 3.9k

Countries citing papers authored by John D. Sheppard

Since Specialization
Citations

This map shows the geographic impact of John D. Sheppard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Sheppard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Sheppard more than expected).

Fields of papers citing papers by John D. Sheppard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Sheppard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Sheppard. The network helps show where John D. Sheppard may publish in the future.

Co-authorship network of co-authors of John D. Sheppard

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Sheppard. A scholar is included among the top collaborators of John D. Sheppard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Sheppard. John D. Sheppard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaercher, Thomas, et al.. (2024). Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease. Graefe s Archive for Clinical and Experimental Ophthalmology. 263(4). 1051–1060. 2 indexed citations
2.
Karpecki, Paul & John D. Sheppard. (2023). Perfluorohexyloctane ophthalmic solution: a review of a prescription treatment for dry eye disease that directly targets tear evaporation. Expert Review of Ophthalmology. 18(6). 355–364.
3.
Markoulli, Maria, Sumayya Ahmad, Jayashree Arcot, et al.. (2023). TFOS Lifestyle: Impact of nutrition on the ocular surface. The Ocular Surface. 29. 226–271. 21 indexed citations
4.
Sheppard, John D., Paul Karpecki, Michael B. Raizman, et al.. (2023). Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?. Optometry and Vision Science. 100(2). 164–169. 7 indexed citations
5.
Clark, David L., Paul Karpecki, Anne Marie Salapatek, John D. Sheppard, & Todd C. Brady. (2022). Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure. SHILAP Revista de lepidopterología. 11 indexed citations
6.
Sheppard, John D., Jodi Luchs, Ranjan Malhotra, et al.. (2019). Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study. Eye & Contact Lens Science & Clinical Practice. 46(1). S14–S19. 20 indexed citations
7.
Sheppard, John D., Todd C. Brady, C. Stephen Foster, Kenneth J. Mandell, & Scott L. Young. (2017). A Randomized, Comparator-Controlled Phase 2 Clinical Trial of ADX-102 Ophthalmic Solution in Noninfectious Anterior Uveitis. Investigative Ophthalmology & Visual Science. 58(8). 1231–1231. 4 indexed citations
8.
Goldstein, Michael H., Joseph R. Martel, Kenneth Sall, et al.. (2016). Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye & Contact Lens Science & Clinical Practice. 43(5). 287–296. 19 indexed citations
9.
Nguyen, Quan Dong, Pauline T. Merrill, Glenn J. Jaffe, et al.. (2016). Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet. 388(10050). 1183–1192. 331 indexed citations breakdown →
10.
Cavet, Megan E., Heleen H. DeCory, & John D. Sheppard. (2016). Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Investigative Ophthalmology & Visual Science. 57(12). 5405–5405. 1 indexed citations
11.
Sheppard, John D., Avani Joshi, Manish Mittal, et al.. (2015). Effect of adalimumab on visual functioning (VFQ-25) in VISUAL-1 trial patients with non-anterior non-infectious uveitis. Investigative Ophthalmology & Visual Science. 56(7). 1723–1723. 2 indexed citations
12.
13.
Sheppard, John D., Eric D. Donnenfeld, Edward J. Holland, et al.. (2014). Effect of Loteprednol Etabonate 0.5% on Initiation of Dry Eye Treatment With Topical Cyclosporine 0.05%. Eye & Contact Lens Science & Clinical Practice. 40(5). 289–296. 55 indexed citations
14.
Phister, Trevor G., et al.. (2011). Characterization of Hybrid Strains of Saccharomyces Pastorianus for Desiccation Tolerance. Journal of the American Society of Brewing Chemists. 69(2). 108–115. 4 indexed citations
15.
Sheppard, John D. & Eric D. Donnenfeld. (2008). Topical Loteprednol 0.5% Induction Therapy Improves Topical Cyclosporine Emulsion Tolerability in Chronic Dry Eye Disease. Investigative Ophthalmology & Visual Science. 49(13). 99–99. 1 indexed citations
16.
Hosseini, Alireza, Frank A. Lattanzio, S. S. Samudre, et al.. (2008). Topical Phosphorodiamidate Morpholino Oligomer Antisense Compounds Effectivly Delay Cornea Rejection in a Transplant Rat Model. Investigative Ophthalmology & Visual Science. 49(13). 5764–5764. 1 indexed citations
17.
Sheppard, John D., et al.. (2007). Vicinal Diketone Production and Amino Acid Uptake by Two Active Dry Lager Yeasts during Beer Fermentation. Journal of the American Society of Brewing Chemists. 65(3). 138–144. 17 indexed citations
18.
Sheppard, John D., et al.. (2004). Omalizumab Decreases Steroid Requirements in Patients with Ocular Allergy. Investigative Ophthalmology & Visual Science. 45(13). 4847–4847. 1 indexed citations
19.
Williams, Patricia B., et al.. (2004). A Comprehensive System for Pterygium Classification. Investigative Ophthalmology & Visual Science. 45(13). 2940–2940. 11 indexed citations
20.
Samudre, S. S., et al.. (2003). Does Confocal Microscopy Effectively Predict Cellular Effects of Steroid-treated Acute Uveitis?. Investigative Ophthalmology & Visual Science. 44(13). 727–727. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith Flanagan Breakdown of academic impact, for papers by Makoto Itoh Breakdown of academic impact, for papers by Liqiang Wang Breakdown of academic impact, for papers by Gert Doekes Breakdown of academic impact, for papers by Naoki Inoue Breakdown of academic impact, for papers by Els Adriaens Breakdown of academic impact, for papers by Jingjing Wang Breakdown of academic impact, for papers by Dongmei Deng Breakdown of academic impact, for papers by Viswanath P. Kurup Breakdown of academic impact, for papers by Yoshimi Niwano
Rankless by CCL
2026